ILiAD Biotechnologies, a late-stage biotech development company, has selected Emmet Group, a global CRO, to conducts upcoming Phase III studies of its lead pertussis vaccine candidate, BPZE1.
The company selected Emmet due to their expertise in vaccine development, as well as their strong local market presence and integrated technologies.
This follows the successful collaboration on ILiAD’s Phase II IB-201P BPZE1 study.
Verdix AI — part of the Emmes Group, will provide Advantage eClinical, its proprietary AI technology, to expedite and improve the efficiency of the study.
The companies plan to run studies across North, Central and South America, as well as the UK.
CEO of ILiAD Biotechnologies, Dr Keith Rubin, commented, “VaxTrials’ specialisation in vaccines and Veridix AI’s advanced technological capabilities will be instrumental in executing our BPZE1 vaccine clinical development plan.”
CEO of Emmes Group, Sastry Chilukuri said: ”We look forward to working closely with ILiAD’s clinical development team on this promising new vaccine, which could significantly reduce the transmissibility and incidence of B. pertussis, particularly in vulnerable populations.”
